Synergistic effects of A. soehngenii and metformin in T2D
This randomized, double-blind, placebo-controlled trial investigated the impact of 14-day Anaerobutyricum soehngenii L2-7 supplementation on postprandial glucose levels in 25 white Dutch males with type 2 diabetes (T2D) on stable metformin therapy. The primary endpoint was the effect of A. soehngenii versus placebo on glucose excursions and variability as determined by continuous glucose monitoring. Secondary endpoints were changes in ambulatory 24-hours blood pressure; incretins; circulating metabolites and excursions of plasma short-chain fatty acids (SCFA) and bile acids upon a standardized meal. Results showed that A. soehngenii supplementation for 14-days significantly improved glycemic variability and mean arterial blood pressure, without notable changes in SCFA, bile acids, incretin levels, or anthropometric parameters as compared to placebo-treated controls. Although well-tolerated and effective in improving glycemic control in the intervention group, further research in larger and more diverse populations is needed to generalize these findings.
